Mechanism of EGR2 in Allergic Rhinitis

Sponsor

Zu-xia Ma (Other)

Overall Status

Enrolling by invitation

CT.gov ID

NCT05724290

Collaborator

(none)

Enrollment

Location

Arms

3.1

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

EGR2 may be a target for the treatment of nasal polyps.

Condition or Disease	Intervention/Treatment	Phase
Rhinitis, Allergic	Genetic: EGR2	Phase 1

Detailed Description

There is much debate about the etiology of nasal polyps, so the pathogenesis of nasal polyps still needs to be clarified. Surgery for noninflammatory nasal polyps may be better control, but surgery is not effective for recurrent sinusitis and nasal polyps. Therefore, more research is needed to determine the best targeted therapy for nasal polyps. We found that EGR2 expression was upregulated in CRSwNP patients with allergic rhinitis.In addition, the expression of EGR2 in CRSwNP mucosa was significantly higher than that in the control group, and the expression of EGR2 in CRSwNP with allergic rhinitis was higher than that in CRSwNP without allergic rhinitis. EGR2 may be involved in the pathogenesis of nasal polyps, and may also be related to the severity and recurrence of nasal polyps. EGR2 may be a target for the treatment of nasal polyps.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

3 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Basic Science

Official Title:

The Regulatory Mechanism of EGR2 Mediated by miR-150-5p on Allergic Rhinitis

Actual Study Start Date :

Jan 30, 2023

Actual Primary Completion Date :

Feb 1, 2023

Anticipated Study Completion Date :

May 5, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: immunohistochemistry Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry	Genetic: EGR2 We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.
Experimental: WestBlot Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by Western Blot.	Genetic: EGR2 We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Arm

Intervention/Treatment

Experimental: immunohistochemistry

Thirty-eight patients with confirmed nasal polyps (20 with primary CRSwNP and allergic rhinitis (AR) and 18 with CRSWNP) and 20 patients with chronic hypertrophic rhinitis were included. The nasal polyps and mucosal specimens of all patients were collected and analyzed by immunohistochemistry

Genetic: EGR2

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Experimental: WestBlot

Genetic: EGR2

We investigated the expression of EGR2 in patients with nasal polyps through immunohistochemistry.

Outcome Measures

Primary Outcome Measures

expression of EGR2 [one months]
expression of EGR2 were analyzed by immunohistochemistry and Western Blot

Eligibility Criteria

Criteria

Ages Eligible for Study:

16 Years to 76 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All patients were stopped by systemic or topical corticosteroid treatment at least one month before the study.

Exclusion Criteria:

Patients had NPs accompanied by choanal polyps, fungal nasal sinusitis, cystic fibrosis, acute upper airway upper infection or other systemic diseases.